Expectant management or conization for persistent low-grade cervical intraepithelial neoplasia: Analysis of 5-year outcomes

To investigate to describe outcomes of conization or expectant management for women with persistent (>24 months) low-grade cervical intra-epithelial neoplasia.
This is a retrospective analysis focusing on five-year outcomes after persistent, histologically confirmed, low-grade cervical intra-epithelial neoplasia undergoing conization or expectant management.

Volunteering in a pediatric oncology unit: Motivations and duration

Volunteers play an essential role in pediatric oncology. While they are driven by personal motivations, they usually receive specific training that may support or reshape their goals.
We conducted a questionnaire-based survey to assess demographics, motivations, and satisfaction among eight associations/non-profit organizations, representing approximately 120 volunteers. The objectives were to explore the nature and correlations of their motivations to evaluate the sustainability of their engagement.

Trends in histological subtypes of cutaneous melanoma in the Netherlands from 1989 to 2023 – Influence of sunlight exposure and overdiagnosis

Melanoma incidence has continued to increase over the past decades with unchanged mortality. Different sunshine exposures across the generations complicate the interpretation of the trends. It is further suggested that half of the rising incidence rate is caused by overdiagnosis. We compared the time trends in the major but not all sunlight-related histological subtypes of cutaneous melanoma in the Netherlands in 1989-2023.

Nutritional status as a risk factor for adverse events associated with L-Asparaginase in children with acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, and asparaginase (ASNase) is a key component of its treatment. However, ASNase is frequently associated with adverse events (AEs), such as pancreatitis and hypersensitivity reactions particularly with the Escherichia coli derived formulation (L-Asp) which may be influenced by nutritional status.

Synergistic effects of XPO1 inhibitors combined with CD19 CAR-T cells in TP53-mutated DLBCL

Diffuse large B-cell lymphoma (DLBCL) is mostly curable by chemotherapy, but p53 mutations limit the therapeutic effect of DLBCL. Although chimeric antigen receptor (CAR) T cells have made revolutionary progress in the treatment of DLBCL, p53 mutations still lead to drug resistance and/or relapse of DLBCL, affecting the prognosis of lymphoma. Therefore, the project aims to explore additional therapeutic strategies to improve the prognosis of DLBCL with p53 mutations.

LDCT-based lung cancer screening and small cell lung cancer: Limited but non-negligible impact on survival. A brief report

Low-dose computed tomography (LDCT)-based lung cancer screening (LCS) seems to have very limited impact on small cell lung cancer (SCLC) outcomes. This study aims at describing frequency and outcomes of SCLC in a large LCS population.
Patients diagnosed with SCLC among the total population enrolled in three different trials (n = 7473) were selected for the present analysis.

From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching

Patients with HER2+ breast cancer (BC) can receive pertuzumab/trastuzumab (PT) subcutaneous (SC) or intravenous (IV) with similar efficacy. This study explores patients and healthcare professionals (HCPs) perceptions post-PT-SC implementation, alongside a pharmacoeconomic analysis.
This multicentre observational study included semi-structured interviews with HER2+ BC patients (SC or IV) and HCPs from six Lombardy (Italy) BC units plus a pharmacoeconomic analysis of organisational and cost impact. Data were analysed using descriptive statistics and thematic analysis to identify key themes: safety perception, treatment comfort, and trust issues.

Letrozole for hormone receptor–positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial

Epidemiological and retrospective studies suggest that letrozole may improve outcomes in low-grade serous carcinoma of the ovary (LGSCO) by targeting estrogen-driven tumor progression.
We designed a multicenter, randomized, open-label, phase III trial to compare letrozole versus standard chemotherapy (carboplatin plus paclitaxel) in prolonging progression-free survival (PFS). Secondary endpoints include overall survival (OS), objective response rate (ORR), quality of life (MENQoL), and musculoskeletal pain (BPI-SF).

Volume 111 Issue 6, December 2025

Read the latest issue. It contains the following articles:
The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives
Delphi Study on the creation of a Committee of patients, caregivers, and representatives of patient associations
The e-BRAVE study: A prospective web-based cohort and biobank of women carriers of BRCA mutations
An indirect approach to identify the healthcare services for thyroid and melanoma cancer patients in Italy: Epicost-2 project
Association of APOC1 levels and nutritional indices with clinicopathological features and prognostic value in patients with DLBCL
Predicting severe toxicity after head-and-neck cancer RT: Validation of the synergist role of a biological marker and dosimetry
Effects of uniportal 3D video-assisted thoracic surgery lobectomy on postoperative pain and immune function in patients with NSCLC
Medication-related jaw osteonecrosis in metastatic RCC treated with VEGFR-TKIs ± IO and bone agents: A real-world analysis

Abdominal specimen retrieval in endometrial cancer patients with large uteri

Endometrial cancer surgery has a low risk of specimen fragmentation, but removing large uteri can be challenging. This study aimed to assess whether the use of minilaparotomic incision for specimen retrieval compromises the benefits of minimally invasive surgery in endometrial cancer patients with a large uterus or utero-vaginal discrepancy.
This is a retrospective multi-institutional study, including endometrial cancer patients with FIGO 2009 clinical stage I–II, undergoing minimally invasive staging surgery (laparoscopic or robot-assisted) followed by minilaparotomic specimen retrieval. A propensity-matched algorithm was used to compare outcomes of minimally invasive staging with open surgery.